Standard Biotools (LAB) Income from Continuing Operations (2010 - 2026)

Standard Biotools (LAB) has 17 years of Income from Continuing Operations data on file, last reported at 14626000.0 in Q1 2026.

• Income from Continuing Operations for Q1 2026 came in at 14626000.0, up 37.47% year-over-year; the trailing twelve-month figure through Mar 2026 was 18485000.0 (up 158.58% YoY), and the FY2025 annual result was 9706000.0, up 139.48% from the prior year.
• Income from Continuing Operations fell to 14626000.0 in Q1 2026 per LAB's latest filing, from 82477000.0 in the prior quarter.
• Over five years, Income from Continuing Operations peaked at 82477000.0 in Q4 2025 and troughed at 76262000.0 in Q1 2022.
• A 5-year average of 14748529.41 and a median of 21047000.0 in 2023 frame the typical range for Income from Continuing Operations.
• The sharpest annual moves came in 2022 and 2023: Income from Continuing Operations tumbled 305.82% in 2022, then soared 1156.13% in 2023.
• A 5-year view of Income from Continuing Operations shows it stood at 1958000.0 in 2022, then soared by 1156.13% to 20679000.0 in 2023, then soared by 89.47% to 39180000.0 in 2024, then jumped by 110.51% to 82477000.0 in 2025, then slumped by 117.73% to 14626000.0 in 2026.
• Business Quant data shows LAB's Income from Continuing Operations at 14626000.0 in Q1 2026, 82477000.0 in Q4 2025, and 31684000.0 in Q3 2025.